AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Vivesto Major Shareholding Notification 2016

Nov 1, 2016

3124_rns_2016-11-01_a8a19d6d-2688-4434-b18d-aba660d2771a.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

PRESS RELEASE

Oasmia Pharmaceutical Announces Change in Ownership

Uppsala, Sweden, November 1, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has divested its shareholder position in Oasmia in its entirety to a consortium of professional Swedish and international investors.

For more information, please contact:

Julian Aleksov Tel: +46 18 50 54 40 E-mail: [email protected]

Notes to editors:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drugdelivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 21.10 CET on November 1, 2016."